MARKET

AKTX

AKTX

Akari Therapeutics Plc
NASDAQ
0.1500
-0.0293
-16.34%
After Hours: 0.1575 +0.0075 +5.00% 17:22 03/30 EDT
OPEN
0.1734
PREV CLOSE
0.1793
HIGH
0.1849
LOW
0.1420
VOLUME
1.48M
TURNOVER
0
52 WEEK HIGH
1.610
52 WEEK LOW
0.1420
MARKET CAP
11.17M
P/E (TTM)
-0.4167
1D
5D
1M
3M
1Y
5Y
Akari Therapeutics to raise $4M in stock offering
Seeking Alpha · 16h ago
Akari Therapeutics Prices $4 Million Registered Direct Offering; Shares Down
Akari Therapeutics Prices $4 Million Registered Direct Offering; Shares Down
MT Newswires · 19h ago
Poland And U.K. Regulatory Authorities URPL And MHRA Approve Use Of New, Higher-Yielding Manufacturing Process For Nomacopan In Pivotal Clinical Study
Benzinga · 1d ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 03/13 21:32
BRIEF-Akari Therapeutics PLC Says Does Not Hold Any Deposits Or Securities At SVB, Has No Accounts At SVB
Reuters · 03/13 13:55
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 03/03 13:06
BRIEF-Akari Therapeutics Announces Presentation Of Case Study From Phase 3 Part A Clinical Trial Of Nomacopan
Reuters · 02/21 13:39
Akari Therapeutics Announces Presentation Of A Case Study From Phase 3 Part A Clinical Trial Of Nomacopan In Pediatric HSCT-TMA As A Late-Breaker At The Transplantation & Cellular Therapy Tandem Meetings
Benzinga · 02/21 13:14
More
About AKTX
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement C5. Its lead product candidate, Nomacopan, is a recombinant small protein (16,740 Da) that acts on complement component-C5, preventing release of C5a and formation of C5b-9 (membrane attack complex (MAC)), and independently also inhibits leukotriene B4, or LTB4, activity, both elements that are co-located as part of the immune/inflammatory response. The Company’s pipeline includes two late-stage programs for bullous pemphigoid (BP) and thrombotic microangiopathy (TMA), as well as earlier stage research and development programs in eye and lung diseases with unmet need. Its pre-clinical programs include Nomacopan LA, Votucalis and others.

Webull offers kinds of Akari Therapeutics PLC (ADR) stock information, including NASDAQ:AKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKTX stock methods without spending real money on the virtual paper trading platform.